[Intravenous immunoglobulin therapy in Vogt-Koyanagi-Harada syndrome]

Neurologia. 2004 Sep;19(7):401-3.
[Article in Spanish]

Abstract

Vogt-Koyanagi-Harada (VKH) syndrome or uveomeningitic syndrome is a disease affecting several organs: eye (bilateral uveitis, exudative retinal detachments), ear (tinnitus, dysacousia), skin and hair (vitiligo, alopecia, poliosis) and the nervous system (meningism, headache, pleocytosis in cerebrospinal fluid). The etiology remains unknown but it is probably a cell-mediated autoimmune disorder in individuals genetically susceptible to antigenic components of melanocytes. We report a 25 year old patient with VKH syndrome treated with intravenous steroid therapy and cycles of intravenous immunoglobulin with good clinical response. We concluded that treatment of the VKH syndrome should be early but definitely aggressive with high doses of systemic corticosteroids and intravenous immunoglobulin, assessing the maintenance of the latter by cycles.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adult
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Male
  • Uveomeningoencephalitic Syndrome / drug therapy*

Substances

  • Immunoglobulins, Intravenous